# Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple

Source: https://onco.cc/trials/nct04162210/  
OnCo record `nct04162210` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04162210 by GlaxoSmithKline, with 325 participants enrolled, started 2020-04-02 and due to reach its primary completion in 2022-09-12. Interventions recorded: Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone). Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: DREAMM 3
- Tags: ctgov-ingest
- Registry id: NCT04162210
- Phase: 3
- Setting: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
- Sponsor: GlaxoSmithKline
- Enrolled: 325
- Outcomes: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG): Belantamab Mafodotin 11.2 months vs Pomalidomide Plus Dexamethasone 7 months, HR 1.03; Overall Survival (OS): Belantamab Mafodotin 24 months vs Pomalidomide Plus Dexamethasone 22.9 months, HR 0.98; Overall Response Rate (ORR): Belantamab Mafodotin 41% vs Pomalidomide Plus Dexamethasone 36%

## Sources

- ClinicalTrials.gov NCT04162210: https://clinicaltrials.gov/study/NCT04162210

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct04162210.json